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ess: iohno@tohoku-phaSummary Diffuse panbronchiolitis (DPB) is a life-threatening airway disease in
which neutrophils persistently and massively emigrating to the airways cause
progressive and irreversible tissue damage. However, the pathogenesis of the airway
inflammation remains unclear. The failure of non-inflammatory removal of
emigrating neutrophils due to delayed apoptosis has been proposed as a mechanism
by which the neutrophilic inflammation persists. Therefore, we aimed to investigate
whether an activity that delays neutrophil apoptosis is present at the inflamed sites
in DPB. Neutrophils isolated from normal volunteers were cultured with sputum
extracts of patients with DPB, and viability and apoptosis of neutrophil was
evaluated for the culture period. Neutrophils cultured with sputum extracts for 2
and 3 days showed significantly enhanced survival compared to those with medium
alone. The neutrophil survival-enhancing activity in sputum extracts was heat-labile
and partially, but significantly, neutralized with anti-human GM-CSF, but not with
anti-human G-CSF antibody. The enhancement of neutrophil survival was associated
with an inhibition of apoptosis demonstrated by cytology, TUNEL assay and DNA
fragmentation analysis. These results suggest that neutrophil apoptosis is prevented
by survival-enhancing factors including GM-CSF in the airways of DPB, leading to
neutrophil death by necrosis that causes further recruitment and activation of
neutrophils.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Neutrophil survival by DPB sputum 911Introduction
Diffuse panbronchiolitis (DPB) was first described
by Homma and coworkers as a chronic inflammatory
disorder of the airways histologically characterized
by peribronchiolitis with the infiltration of lympho-
cytes and plasma cells.1,2 DPB is not uncommon in
Japan and largely restricted geographically to the
Far East. A small number of patients have been
confirmed in Korea3,4 and China.5 Only sporadic
cases have been reported in US 6–8 and Europe.9–11
Some genetic component is suggested by a frequent
HLA haplotype, HLA B54, in patients with DPB.1,2
Cystic fibrosis (CF) is the most common recessively
inherited disorder in Caucasian populations that is
caused by the mutation of a single gene coding CF
transmembrane conductance regulator (CFTR).
CFTR dysfunction predisposes to a wide range of
multi-organ clinical manifestations including the
respiratory tract.12,13 Although the predisposing
factors to DPB and CF are different, the two
diseases have similar features in terms of chronic
neutrophilic airway inflammation and a high rate of
respiratory infection with mucoid Pseudomonas
aeruginosa (P. aeruginosa). A persistent and abun-
dant influx of neutrophils to the airway lumen
cause progressive and irreversible damage in air-
way tissues by releasing histotoxic mediators such
as reactive oxygen species and proteolytic en-
zymes. Respiratory failure is the prime cause of
morbidity and mortality in both disorders.2,12,13
Although the overexpression of cytokines and
chemokines, such as TNF, IL-1 and IL-8, and the
infection with P. aeruginosa in the airways are
thought to be involved in the induction of neu-
trophilic airway inflammation,2,14 the mechanisms
underlying the chronic bronchial inflammation are
not fully understood.
Neutrophils have a very short life in the circula-
tion (8–20 h) and in tissues in the absence of
inflammation (1–2 days). Aged neutrophils undergo
apoptosis (programmed cell death) prior to the
phagocytic removal by macrophages. This removal
does not cause the release of toxic mediators from
the neutrophils. Once neutrophils influx to targeted
sites as effector cells they are activated and local
inflammatory mediators delay their apoptotic
death. Activated neutrophils die by necrosis and
release their toxic mediators. For the resolution of
inflammation, apoptosis followed by safe removal
by phagocytes of neutrophils is important. Con-
versely, the failure of non-inflammatory clearance
of emigrating neutrophils due to the prevention of
their apoptosis would result in persistent inflam-
mation and excessive tissue damage as in DPB and
CF. Many factors such as granulocyte-macrophagecolony-stimulating factor (GM-CSF), granulocyte
colony-stimulating factor (G-CSF) and lipopolysac-
charide (LPS), found abundantly at inflammatory
sites, have been demonstrated to be able to
suppress neutrophil apoptosis.15–18
Therefore, we hypothesized that the inhibition of
apoptosis by factors at the site of inflammation
render emigrating neutrophils necrotic, increasing
the airway inflammation and causing it to persist in
DPB. To access our hypothesis, we investigated
whether an activity that enhances the survival of
neutrophils is present at the inflamed sites by
examining the effect of extracts of sputum from
patients with DPB on the survival of neutrophils
isolated from peripheral blood.Materials and methods
Patients studied
We collected sputum expectorated spontaneously
from 8 outpatients with DPB (Table 1). DPB was
defined based on the clinical diagnostic criteria
established by Homma and Yamanaka in 1969 in
collaboration with the Ministry of Health and
Welfare of Japan.19 All patients were non-smokers
and had been treated continuously with theophyl-
line, b2-agonists and expectorants. Their symptoms
were chronic cough and sputum with occasional
exacerbations. During the month preceding the
study, none of the patients had had an acute
exacerbation, nor had been treated with antibio-
tics or corticosteroids. Macrolides were not given to
the patients during the study period. By sputum
culture, the mucoid type of P. aeruginosa was
invariably detected.
Processing of sputum from patients
Sputum was collected in sterile tubes, kept cold
and, immediately after the expectoration, pro-
cessed for the culture of P. aeruginosa, the analysis
of sputum cells and the collection of sputum
extracts. Sputum culture was performed as pre-
viously described.20 P. aeruginosa was identified
with an Enteric/Nonfermenter ID Kit (Becton
Dickinson and Company, Sparks, Maryland) accord-
ing to the manufacturer’s protocol. After the
homogenization with sputasol (Unipath Ltd., Ba-
singstoke, UK), cell differentials were counted and
the viability of sputum cells was assessed by
exclusion of trypan blue dye as previously de-
scribed.21 Sputum extracts were collected as
previously described 22 with some modifications.
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Table 1 Characteristics of patients studied.
Subject No. Age (years) Sex VC* (L) FEV1 (L) Sputum
P. aeruginosa (CFU/ml) Neutrophils
(X106/ml) viability
1 25 F 2.47 1.62 108 48.7 92.3
2 59 F 2.71 2.09 106 22.4 98.2
3 43 F 2.55 1.75 108 66.9 94.5
4 71 F 1.02 0.55 4108 123.4 91.9
5 46 F 2.16 0.92 107 30.8 89.3
6 57 F 2.98 1.38 108 63.0 96.5
7 69 M 2.75 1.68 108 86.3 97.8
8 68 M 2.62 0.50 108 90.5 98.7
*VC, vital capacity; FEV1, forced expiratory volume in one second; CFU, colony forming unit.
K. Nishimaki et al.912Briefly, the purulent portion of sputum was trans-
ferred to a tube followed by the addition of one
volume of physiological saline. After stirred with a
vortex mixer for 2min, the sputum was ultracen-
trifuged at 4 1C for 90min at 40,000 g. Then, the
supernatant was collected, passed through a 0.2-mm
filter (Minisart) (Sartorius AG, Go¨ttingen, Germany),
and stored as the sputum extracts at 20 1C.Neutrophil isolation and culture conditions
Heparinized venous blood was obtained from
healthy volunteers. Neutrophils were isolated by
dextran sedimentation and centrifugation on a
Ficoll-Paque (Amersham Pharmacia Biotech, Uppsa-
la, Sweden) as previously described23 with some
modifications. Neutrophils (496% pure, 498%
viable, by exclusion of trypan blue dye) were
resuspended at 106 cells/ml in RPMI 1640 (GIBCO
BRL, Life Technologies, Grand Island, NY) supple-
mented with 10% fetal bovine serum (Cansers
International Inc., Toronto, Canada), and incubated
in 24-well culture plates (Becton Dickinson Lab-
ware, Franklin Lakes, NJ) (1ml/well) for three days
at 37 1C in a humidified atmosphere of 5% CO2 in air.
The cultures were performed in triplicate in the
presence or absence of sputum extracts at the
indicated concentration, recombinant human GM-
CSF (TECHNO Corporation, Minneapolis, MN)
(500 mg/ml) or LPS (from Escherichiya coli 026:B6,
Sigma Chemical Co., St. Louis, MO) (1 mg/ml) as a
positive control. In some experiments, sputum
extracts and LPS were preincubated at 4 or 85 1C
for 15min, or sputum extracts and human GM-CSF
were preincubated overnight at 4 1C with an anti-
human GM-CSF (TECHNO Corporation) (10 mg/ml) oran anti-human G-CSF (10 mg/ml) (R&D System, Inc.,
Minneapolis, MN) mouse monoclonal IgG1 antibody.
The concentrations of antibodies used here were
sufficient to neutralize 500 mg/ml of GM-CSF or
125 ng/ml of G-CSF, respectively, based on the
information provided by the manufacturer. These
concentrations of GM-CSF and G-CSF have been
reported to inhibit neutrophil apoptosis by
50–70%.23,24 At each time point, after gentle
resuspension, viable cells were counted by exclu-
sion of trypan blue dye for each well in a blind
fashion. Viability was calculated by the following
formula: viability (%) ¼ [the number of viable cells
/that of viable cells at the beginning of culture
(106 cells)]  100. The mean value of triplicate
determinations was used as that for each condition.
For each condition examined, cell smears were
prepared from triplicate incubations with cytospin
(Cytospin 2, Shandon, Runcorn, UK) for further
examination.Evaluation of neutrophil apoptosis
Neutrophil apoptosis was evaluated by cytology,
terminal transferase dUTP nick end-labeling (TU-
NEL) assay, and DNA fragmentation analysis. Cytos-
pin preparations of neutrophils were stained with a
Diff-Quick stain set (Baxter, Miami, FL), and
examined under light microscopy at a magnification
of 1000 in a blind fashion. Apoptotic neutrophils
were defined as cells containing one or more
characteristic darkly stained pyknotic nuclei.25
Results were expressed as percentage of apoptotic
cells in more than 500 cells counted on duplicate
slides for each condition. TUNEL assay was per-
formed using an ApopTag Apoptosis Detection kit
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Neutrophil survival by DPB sputum 913(Serologicals Corporation, Norcross, GA) according
to the manufacturer’s protocol. Using an Automatic
Nucleic Acid Isolation System (NA-1000) (KURABO,
Osaka, Japan), DNA was extracted from neutrophils
cultured for 24 h with medium alone, sputum
extracts or LPS as mentioned above. Two micro-
grams of each DNA sample and a molecular size
marker (1kb DNA Ladder, GIBCO BRL) were heated
at 60 1C for 10min and then electrophoresed
through 1.8% agarose (Nippon Gene Co. Ltd.,
Toyama, Japan) gel. After staining in ethidium
bromide (Sigma) (10 mg/ml) the gel was viewed
under UV light.Figure 1 Time-dependent effects of sputum extracts on
neutrophil survival. Neutrophils (106/ml) were cultured
with LPS (1 mg/ml) (closed circles, n ¼ 6), sputum
extracts (10%) (closed triangles, n ¼ 8) and medium
alone (open circles, n ¼ 6). At each time point, viability
was evaluated as described in ‘Materials and methods’,
and expressed as mean7SEM. Po0:01 compared to
medium alone.
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Values are presented as mean7SEM. Mann–Whitney
U-test was used to compare the differences
between the values except for the values in the
time-course experiments in which the differences
were estimated with one-way analysis of variance
and Fisher’s PLSD method. These analyses were
performed using StatView 4.11 (Abacus Concepts,
Berkeley, CA) for Macintosh. The level of signifi-
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Figure 2 Dose-dependent effects of sputum extracts on
neutrophil survival. Neutrophils (106/ml) were cultured
for 2 days with sputum extracts at various concentrations
(n ¼ 6 at 0% and n ¼ 8 at the other concentrations).
Viability was evaluated as described in ‘Materials and
methods’, and expressed with SEM. Po0:05 and Po0:01
compared to 0%.Results
Enhancement of neutrophil survival by
sputum extracts
The viability of neutrophils cultured with medium
alone was 72.779.5% at day 1, 36.775.7% at day 2
and 10.273.3% at day 3 (n ¼ 6). In contrast,
although not significantly different at day 1
(95.076.9%, n ¼ 8), the viability of neutrophils
cultured with sputum extracts (10%) was signifi-
cantly higher than that with medium alone at days
2 (74.176.9%, n ¼ 8; Po0:01) and 3 (43.977.2%,
n ¼ 8; Po0:01), and similar to that with LPS
(94.775.5% at day 1, 86.9714.4% at day 2 and
45.479.9% at day 3, n ¼ 6) (Fig. 1). The effect of
the sputum extracts on neutrophil survival was also
dose dependent (Fig. 2). The viability of neutro-
phils at day 2 was significantly enhanced in the
presence of concentrations of sputum extracts of 5
(54.578.5%, n ¼ 8; Po0:05), 10 (76.477.2%, n ¼
8; Po0:01) and 20% (89.0711.5%, n ¼ 8; Po0:01)
compared with that in medium alone (38.176.0%,
n ¼ 6), but not significantly different in the
presence of 2.5 (48.376.9%, n ¼ 8) and 1.25%
(34.279.1%, n ¼ 8).Characterization of the neutrophil survival-
enhancing activity in sputum extracts
To examine the heat-stability of the neutrophil
survival-enhancing activity in the sputum extracts,
the neutrophils were cultured for 2 days with 10%
sputum extracts pretreated with or without heating
(Fig. 3). Compared with the viability of neutrophils
with non-heated sputum extracts (70.075.6%,
n ¼ 8), that with heat-treated sputum extracts
(32.971.5%, n ¼ 8; Po0:01) was significantly de-
creased to the level of that with medium alone
(38.077.6%, n ¼ 6), while heat treatment
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K. Nishimaki et al.914(75.579.5%, n ¼ 6) did not show any effect at all
on the neutrophil survival-enhancing activity by LPS
(70.075.6%, n ¼ 6), as expected. The neutrophil
survival-enhancing activity in the sputum extracts
was also inhibited partially but significantly by
the preincubation with anti-GM-CSF antibody
(52.273.3%, n ¼ 8; Po0:05), but not with anti-
G-CSF antibody (68.573.5%, n ¼ 8) (Fig. 3). Anti-Figure 4 Cytological appearance of cultured neutrophils. Ne
(A, C) and presence (B, D) of sputum extracts. Cytospin prep
TUNEL (C, D) as described in ‘Materials and methods’. Arrow
apoptosis, and arrow heads in C those positive for TUNEL (m
medium
LPS
LPS/heated
sputum extracts
sputum extracts/heated
sputum extracts/anti GM-CSF
sputum extracts/anti G-CSF
NS
#
*
NS
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Figure 3 Characterization of neutrophil survival-enhan-
cing activity in sputum extracts. Neutrophils (106/ml)
were cultured for 2 days with medium alone (n ¼ 6), LPS
(1mg/ml) (n ¼ 6) and sputum extracts (10%) (n ¼ 8) with
or without heating, and sputum extracts (10%) (n ¼ 8)
preincubated with anti-GM-CSF (10 mg/ml) or anti-G-CSF
(10 mg/ml) antibody. Viability was evaluated as described
in ‘Materials and methods’, and expressed with SEM.
Po0:05; Po0:01; NS, not significant.GM-CSF antibody did not show any inhibitory effect
on the viability of cells cultured with medium alone
(36.373.9%, n ¼ 4). The increased viability of
neutrophils by GM-CSF (71.873.0%, n ¼ 4) was
completely abolished by anti-GM-CSF antibody
(33.372.7%, n ¼ 4; Po0:01).Inhibition of neutrophil apoptosis by sputum
extracts
To examine whether prolongation of neutrophil
survival was due to the inhibition of apoptosis,
cytology, TUNEL staining and DNA fragmentation
analysis were performed. Based on the cell mor-
phology, 53.376.6% (n ¼ 6) of cells were apoptotic
24 h after the culture with medium alone (Fig. 4A).
In contrast, the percentage of apoptotic cells in
neutrophils cultured with 10% sputum extracts was
significantly reduced (11.072.7%, n ¼ 8; Po0:01)
(Fig. 4B), which was similar to that with LPS
(11.073.5%, n ¼ 6). The number of cells positive
for TUNEL staining was apparently decreased in the
culture with sputum extracts (Fig. 4D) compared
with those without sputum extracts (Fig. 4C). DNA
fragmentation with the characteristic ‘ladder’ of
DNA fragments in multiples of 180 bp, which was
clear in neutrophils cultured with medium alone,
was not as apparent in those with sputum extracts
such as with LPS (Fig. 5).utrophils (106/ml) were cultured for 1 day in the absence
arations were subjected to Diff-Quick staining (A, B) and
s in A and B indicate cells with morphological features of
agnification  1000).
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Figure 5 Agarose gel electrophoresis of DNA isolated
from neutrophils. DNA was isolated from neutrophils
(106/ml) cultured for 1 day with medium alone (lane 1),
LPS (1mg/ml) (lane 2) or sputum extracts (lane 3), and
electrophoresed as described in ‘Materials and methods’.
Lane M is a size marker. Arrows indicate positions of such
size of DNAs as shown on left side.
Neutrophil survival by DPB sputum 915Discussion
We demonstrated here for the first time that a
neutrophil survival-enhancing activity due to a
reduction of apoptosis is present in the sputum of
patients with DPB, and that this activity is
attributable, at least in part, to GM-CSF but not
to G-CSF and LPS. There is increasing evidence by a
number of in vitro studies that several inflamma-
tory mediators, including IL-1b, IL-2, IL-8, IL-15,
IFN-g, G-CSF, GM-CSF, C5a, platelet-activating
factor and leukotriene B4 (LTB4), suppress neutro-
phil apoptosis, thus enhancing its survival. The
effects of IL-6 and TNFa on neutrophil survival are
variable.15–18 In sputum and bronchoalveolar lavage
fluid (BALF) of patients with DPB a high concentra-
tion of IL-1b, TNFa, IL-8 and LTB4 are found.
2 The
bronchiolar epithelial cells in patients with DPB
have been demonstrated, by immunohistochemis-
try on lung biopsy tissues, to strongly express GM-
CSF,26 although the content of GM-CSF has not been
reported. P. aeruginosa, that persistently colonizes
the airways of DPB, has been shown to stimulatebronchial epithelial cells to release neutrophil
survival-enhancing activity that is neutralized by
anti-GM-CSF and anti-G-CSF antibody.27 The sputum
studied here from which P. aeruginosa was isolated
would be rich in LPS, which has a potential to
enhance neutrophil survival.16 Therefore, we fo-
cused on GM-CSF, G-CSF and LPS as candidates of
the neutrophil survival-enhancing activity in the
sputum. Since the activity in the sputum was heat-
labile and partially neutralized by anti-GM-CSF, this
activity might be attributed to GM-CSF and other
proteins such as IL-1b, IL-8, TNFa and C5a. Although
we measured the GM-CSF content in sputum
extracts by enzyme-linked immunosorbent assay
(ELISA) in preliminary experiments, the concentra-
tion in all samples was lower than 10 pg/ml, which
is the sensitivity of ELISA kits (R&D System Inc.) we
use (data not shown). Nevertheless, we assume
that GM-CSF was present in the sputum of DPB
patients because GM-CSF has been demonstrated to
be able to enhance neutrophil survival even at
concentrations as low as 5 pg/ml,28,29 and because
the antibody specific for GM-CSF indeed signifi-
cantly reduced the neutrophil survival enhanced by
the sputum extracts as well that by exogenous GM-
CSF. The possibility cannot be ruled out that
inhibitory factors against ELISA such as proteases
were present in the sputum extracts.30
Given that GM-CSF is present in the sputum of
DPB patients, epithelial cells, neutrophils and
macrophages in the airways could be sources of
GM-CSF. The potential of neutrophils to synthesize
GM-CSF in vivo has been shown by the observation
that neutrophils isolated from peripheral blood
released the molecule after stimulation with
calcium ionophore and phorbol 12-myristate 13-
acetate (PMA).31 Macrophages and bronchial
epithelial cells can produce GM-CSF upon stimula-
tion with TNF, IL-1 and LPS 32 found in the airways
of DPB. Neutrophil elastase, likely to be abundant
in the inflamed airways of DPB patients, is a potent
inducer of GM-CSF in epithelial cells.33 Further-
more, bacterial products from P. aeruginosa, which
was consistently isolated from the sputum of the
DPB patients studied here, such as rhamnolipids
and mucoid exopolysaccharide, have been demon-
strated to stimulate epithelial cells to synthesize
and release GM-CSF.33 A variety of these molecules
at the inflammatory site of DPB could enhance the
local production of GM-CSF, which might be
responsible for the neutrophil survival-enhancing
activity in sputum. Another possibility for the
involvement of GM-CSF in the neutrophil survival
enhancement by the sputum extracts is autocrine/
paracrine mechanisms of GM-CSF by neutrophils
during the culture with the sputum extracts.
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K. Nishimaki et al.916Although the physiological stimulants for GM-CSF
production by neutrophils have not been identified,
the sputum of DPB patients is rich in proinflamma-
tory cytokines and complements capable of acti-
vating neutrophils. Such mechanisms are under
investigation.
Neutrophils are the primary effector cells in the
acute inflammatory response triggered by microbes
or irritants. They are activated to exert their
biologic function and undergo necrosis, with their
disintegration leading to the inevitable disgorge-
ment of large quantities of histotoxic mediators
into normal host tissues. For the limitation of tissue
damage and restitution of tissue homeostasis, the
acute inflammation is finally resolved, where
apoptosis plays an important role in the clearance
of neutrophils from the inflammatory site. Alter-
natively, the failure to induce apoptosis or the
inefficient removal of apoptotic neutrophils would
cause neutrophils to undergo necrosis, which would
favor persistent inflammation. This is supported by
a recent study using caspase-1-deficient mice in
which the lipopolysaccharide-induced inflamma-
tory response in lung was prolonged in association
with impaired neutrophil apoptosis.34 To our knowl-
edge, the present study is the first report showing
the presence of inflammatory cell survival-enhan-
cing activity in chronic inflammatory airway dis-
eases except for bronchial asthma. In the sputum of
asthmatics, eosinophil survival-enhancing activity
was detected and reduced by anti-GM-CSF and anti-
IL-5 antibody.22 Delayed eosinophil apoptosis in-
duced by GM-CSF and IL-5 appears to contribute to
the persistency of eosinophilic inflammation in the
airways that occurs in asthma.35,36 As in bronchial
asthma, our results strongly suggest that the
presence of neutrophil survival-enhancing activity
might be one of the underlying mechanisms of the
chronic inflammatory environment in the airways of
patients with DPB and, by extension, CF.
Recently, long-term, low-dose macrolide treat-
ment has been demonstrated to be effective in
improving the survival rate of patients with DPB37
and the respiratory function in those with CF.38
Anti-inflammatory effects, including the inhibition
of GM-CSF production from monocytes, lung fibro-
blasts and bronchial epithelial cells39 and the
acceleration of neutrophil apoptosis,40 have been
reported as the mechanisms of action of macro-
lide.41 The apoptotic action of macrolides was also
suggested by the observation that the DNA of
neutrophils cultured with sputum from a DPB
patient treated with erythromycin was fragmented
(unpublished observation). These findings support
the idea that the prolongation of neutrophil
survival is involved in the pathogenesis in DPB.In summary, a neutrophil survival-enhancing
activity, partially due to GM-CSF, was detected in
the sputum from patients with DPB who show the
characteristic chronic neutrophilic inflammation.
Our results suggest that delayed neutrophil apop-
tosis is involved in the pathogenesis of DPB and CF.
Further investigation of other factors responsible
for this activity and the regulatory mechanisms for
the expression of these factors, especially in
correlation with P. aeruginosa infection, could lead
to the development of new therapeutic strategies
for reducing the airway inflammation in DPB and CF.Acknowledgments
We are grateful to Mr. Brent Bell for reading the
manuscript.References
1. Homma H, Yamanaka A, Tanimoto S, et al. Diffuse
panbronchiolitis. A disease of the transitional zone of the
lung. Chest 1983;83:63–9.
2. Yanagihara K, Kadoto J, Kohno S. Diffuse panbronchiolitis—
pathophysiology and treatment mechanisms. Int J Antimi-
crob Agents 2001;18:S83–7.
3. Sugiyama Y, Takeuchi K, Yotsumoto H, Takaku F, Maeda H. A
case of diffuse panbronchiolitis in a second generation
Korean male. Nippon Kyobu Shikkan Gakkai Zasshi
1986;24:83–7.
4. Kim YW, Han SK, Shim YS, et al. The first report of diffuse
panbronchiolitis in Korea: five case reports. Intern Med
1992;31:695–701.
5. Tsang KWT, Ooi CGC, Ip MSM, et al. Clinical profiles of
Chinese patients with diffuse panbronchiolitis. Thorax
1998;53:274–80.
6. Fitzgerald JE, King Jr. TE, Lynch DA, Tuder RM, Schwarz MI.
Diffuse panbronchiolitis in the United States. Am J Respir
Crit Care Med 1996;154:497–503.
7. Homer RJ, Khoo L, Smith GJ. Diffuse panbronchiolitis in a
Hispanic man with travel history to Japan. Chest
1995;107:1176–8.
8. Krishnan P, Thachil R, Gillego V. Diffuse panbronchiolitis. A
treatable sinobronchial disease in need of recognition in the
United States. Chest 2002;121:659–61.
9. Poletti V, Patelli M, Poletti G, Bertani T, Spiga L. Diffuse
panbronchiolitis observed in an Italian. Chest 1990;98:
515–6.
10. Tredaniel J, Zalcman G, Gerber F, et al. Diffuse panbronch-
iolitis: efficacy of low-dose erythromycin. Respir Med
1993;87:229–30.
11. Brugiere O, Milleron B, Antoine M, Carette MF, Philippe C,
Mayaud C. Diffuse panbronchiolitis in an Asian immigrant.
Thorax 1996;51:1065–7.
12. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir
Crit Care Med 1996;154:1229–56.
13. Brennan AL, Geddes DM. Cystic fibrosis. Curr Opin Infect Dis
2002;15:175–82.
14. De Rose V. Mechanisms and markers of airway inflammation
in cystic fibrosis. Eur Respir J 2002;19:333–40.
ARTICLE IN PRESS
Neutrophil survival by DPB sputum 91715. Haslett C. Granulocyte apoptosis and its role in the
resolution and control of lung inflammation. Am J Respir
Crit Care Med 1999;160:S5–S11.
16. Ward C, Dransfield I, Chilvers ER, Haslett I, Rossi AG.
Pharmacological manipulation of granulocyte apoptosis:
potential therapeutic targets. Trends Pharmacol Sci
1999;20:503–9.
17. Akgul C, Moulding DA, Edwards SW. Molecular control of
neutrophil apoptosis. FEBS Lett 2001;487:318–22.
18. Simon H-U. Regulation of eosinophil and neutrophil apopto-
sis—similarities and differences. Immunol Rev 2001;
179:156–62.
19. Annual report on the study of diffuse disseminated lung
disease by Homma Hiomi. Grant-in Aid from the Ministry of
Health and Welfare of Japan. 1980. Tokyo, Japan.
20. Nishioka K, Ogiwara H, Ohno I, Tanno Y, Shirato K. The
incidence of respiratory tract pathogens and antimicrobial
susceptibilities of Streptococcus pneumoniae, Haemophilus
influenzae and Moraxella (Branhamella) catarrhalis isolated
between 1990 and 1993. Tohoku J Exp Med 1996;
179:111–21.
21. Hoshi H, Ohno I, Honma M, et al. IL-5, IL-8 and GM-CSF
immunostaining of sputum cells in bronchial asthma and
chronic bronchitis. Clin Exp Allergy 1995;25:720–8.
22. Adachi T, Motojima S, Hirata A, Fukuda T, Makio S. Eosinophil
viability-enhancing activity in sputum from patients with
bronchial asthma, Contributions of interleukin-5 and gran-
ulocyte/macrophage colony-stimulating factor. Am J Respir
Crit Care Med 1995;151:618–23.
23. Lee A, Whyte MK, Haslett C. Inhibition of apoptosis and
prolongation of neutrophil functional longevity by inflam-
matory mediators. J Leukoc Biol 1993;54:283–8.
24. Yamamoto C, Yoshida S, Taniguchi H, Qin MH, Miyamoto H,
Mizuguchi Y. Lipopolysaccharide and granulocyte colony-
stimulating factor delay neutrophil apoptosis and ingestion
by guinea pig macrophages. Infect Immun 1993;61:1972–9.
25. Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM,
Haslett C. Macrophage phagocytosis of aging neutrophils in
inflammation. Programmed cell death in the neutrophil
leads to its recognition by macrophages. J Clin Invest
1989;83:865–75.
26. Todate A, Chida K, Suda T, et al. Increased numbers of
dendritic cells in the bronchiolar tissues of diffuse pan-
bronchiolitis. Am J Respir Crit Care Med 2000;162:148–53.
27. Saba S, Soong G, Greenberg S, Prince A. Bacterial stimula-
tion of epithelial G-CSF and GM-CSF expression promotes
PMN survival in CF airways. Am J Respir Cell Mol Biol
2002;27:561–7.
28. Begley CG, Lopez AF, Nicola NA, et al. Purified colony-
stimulating factors enhance the survival of human neutro-phils and eosinophils in vitro: a rapid and sensitive
microassay for colony-stimulating factors. Blood
1986;68:162–6.
29. Lopez AF, Williamson DJ, Gamble JR, et al. Recombinant
human granulocyte-macrophage colony-stimulating factor
stimulates in vitro mature human neutrophil and eosinophil
function, surface receptor expression, and survival. J Clin
Invest 1986;78:1220–8.
30. Kelly MM, Leigh R, Carruthers S, et al. Increased detection of
interleukin-5 in sputum by addition of protease inhibitors.
Eur Respir J 2001;18:685–91.
31. Kita H, Ohnishi T, Okubo Y, Weiler D, Abrams JS, Gleich GJ.
Granulocyte/macrophage colony-stimulating factor and in-
terleukin 3 release from human peripheral blood eosinophils
and neutrophils. J Exp Med 1991;174:745–8.
32. Hamilton JA. GM-CSF in inflammation and autoimmunity.
Trends Immunol 2002;23:403–8.
33. Bedard M, McClure CD, Schiller NL, Francoeur C, Cantin A,
Denis M. Release of interleukin-8, interleukin-6, and colony-
stimulating factors by upper airway epithelial cells: implica-
tions for cystic fibrosis. Am J Respir Cell Mol Biol
1993;9:455–62.
34. Rowe SJ, Allen L, Ridger VC, Hellewell PG, Whyte MK.
Caspase-1-deficient mice have delayed neutrophil apoptosis
and a prolonged inflammatory response to lipopolysacchar-
ide-induced acute lung injury. J Immunol 2002;169:6401–7.
35. Vignola AM, Chanez P, Chiappara G, et al. Evaluation of
apoptosis of eosinophils, macrophages, and T lymphocytes in
mucosal biopsy specimens of patients with asthma and
chronic bronchitis. J Allergy Clin Immunol 1999;103:
563–73.
36. Kankaanranta H, Lindsay MA, Giembycz MA, Zhang X,
Moilanen E, Barnes PJ. Delayed eosinophil apoptosis in
asthma. J Allergy Clin Immunol 2000;106:77–83.
37. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M.
Improvement of survival in patients with diffuse panbronch-
iolitis treated with low-dose erythromycin. Am J Respir Crit
Care Med 1998;157:1829–32.
38. Equi A, Balfour-Lynn IM, Bush A, Rosethal M. Long term
azithromycin in children with cystic fibrosis: a randomised,
placebo-controlled crossover trial. Lancet
2002;360:978–84.
39. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in
lung disease. Pediatr Pulmonol 2001;31:464–73.
40. Aoshiba K, Nagai A, Konno K. Erythromycin shortens
neutrophil survival by accelerating apoptosis. Antimicrob
Agents Chemother 1995;39:872–7.
41. Koyama H, Geddes DM. Erythromycin and diffuse panbronch-
iolitis. Thorax 1997;52:915–8.
